Home MarketSun Pharma Advanced Research Company Ltd.

Sun Pharma Advanced Research Company Ltd. Stock Info: As on 2018-05-24 15:56:20

Nse

356.05

-3.70(-1.03%)
Change%
52 Week Range
272.00
30.00
532.00
12.00
Open359.05
Day's Range287.80 - 431.70
Value Traded (in ₹ Cr.) 4.43

Bse

355.75

-2.65(-0.74%)
Change %
52 Week Range
273.00
29.00
532.40
12.00
Open361.00
Day's Range286.72 - 430.08
Value Traded (in ₹ Cr.) 0.90

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 169,296,119.00 67.47%
Mutual Funds/UTI 4,912,391.00 1.96%
FII 17,515,455.00 6.98%
Employee 0.00 0.00%
Public 35,301,284.00 14.07%
Government 0.00 0.00%
Others 23,785,467.00 9.48%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 43.20
Basic EPS (Rs.) -4.87
Cash EPS -4.54
BVPerShare Excl 6.47
Operating Revenue 7.33
PBDITPerShare -4.46
Dividend 0.00
NPPerShare -4.87
Current Ratio 1.47
Quick Ratio 1.47
PriceToBV 48.98
Earnings -0.01
PBDIT Margin -60.87
PBT Margin -66.43
NP Margin -66.43
Return On Assets -43.88
Retention Ratios 0.00
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 194.65
Total Expenses 314.92
EBITDA -110.21
PBT -120.27
PAT -120.27
Net Income -120.27
More
Parameter Mar-18 (₹ Cr.) 6M % change
Total Income 42.17
Total Expenses 146.71
EBITDA -108.58
PBT -55.59
PAT -55.59
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 24.69
Net worth 159.65
Investments 9.55
Total Liability 274.04
Total debt 2.59
Net block 70.63
Total Assets 274.04
Parameter Mar-17 (₹ Cr.) 6M % change
Total share capital 23.67
Net worth 29.90
Investments 0.00
Total Liability 162.66
Total debt 55.21
Net block 70.83
Total Assets 162.66
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

371.25 374.25 -0.8
373.5405.5

Banaras Beads Ltd.

53.25 54.45 -2.2
5257

Binani Industries Ltd.

87.85 88.3 -0.51
87.196

Delta Corp Ltd.

231.3 227.9 1.49
224.6271

Dredging Corporation Of India Ltd.

556.85 558.6 -0.31
551604.9

Future Consumer Ltd.

53.9 54.5 -1.1
52.759.7

Gateway Distriparks Ltd.

165.95 167.7 -1.04
164177.55
Company Curr Price Prev. Close Change% W's Low/High

Adani Ports & Special Economic Zone Ltd.

372 373.5 -0.4
372.75418

Alpha Hi-Tech Fuel Ltd.

0.87 0.91 -4.39
0.870.87

Anil Ltd.

28.9 30.4 -4.93
28.928.9

Bagalkot Udyog Ltd.

23.9 25.15 -4.97
23.923.9

Banaras Beads Ltd.

53.45 55.2 -3.17
50.258.75

Binani Industries Ltd.

87.6 88.2 -0.68
8898.8

Brahmanand Himghar Ltd.

4.08 4.29 -4.9
4.084.08
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 128.04
Cash from investing activities 4.71
Cash from financing activities -192.35
Net change in cash -59.58

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
UTI Mid Cap Fund 1.35%
Axis Long Term Equity Fund 0.24%
Axis Focused 25 Fund 1.01%
DSP BlackRock Small Cap Fund 0.31%
UTI Value Opportunities Fund 0.37%
UTI Long Term Advantage Fund - Series III 3.06%

M Venkatesh appointed MRPL MD

M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.

24-05-2018 11:42

TCS expands operations in Florida as part of Transamerica deal

India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.

24-05-2018 11:16

Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April

Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

Kotak India Growth Fund Series 4: change in investment factsheets for April

Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

BLS International to assist Sopra Steria on UK visa renewals

Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.

24-05-2018 10:51

Sun Pharma Advanced posts Q4 net profit of Rs 2.48 cr

The company reported standalone net profit during the quarter stood at Rs 2.48 crore compared to net loss of Rs 32.27 crore in the previous year quarter. Net revenue of the company declined substantially by 51.71 per cent at Rs 20.09 crore in January-March quarter of this fiscal as against Rs 41.60 crore in the corresponding period last year. During January-March quarter, operating expenses dropped by 13.80 per cent to Rs 65.08 crore from Rs 75.50 crore in year ago period. Other Income dipped by 86.10 per cent at Rs 0.52 crore versus (Mar'17 Rs 3.74 crore). Operating Profit surged by 32.71 per cent to Rs -44.99 crore as against Rs -33.90 crore in the year ago period, while Operating Profit Margin (OPM) contracted year-on-year to 174.81 per cent in March quarter. Interest declined by 66.67 per cent y-o-y to Rs 0.01 crore

11-May-2018 03:09 PM

Sun Pharma Advanced - Financial Result Updates

Sun Pharma Advanced Research Company Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.

08-May-2018 07:01 PM

Sun Pharma Advanced - Outcome of Board Meeting

Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Board meeting held on May 08, 2018.

08-May-2018 06:57 PM

Sun Pharma Advanced - Board Meeting-Outcome of Board Meeting

The Board of Directors of the Company at their meeting held from 04:45 pm to 06:45 pm today, inter alia, took on record and duly approved the Audited Financial Results for the quarter and year ended 31st March, 2018 which are enclosed along with the Auditors' Report on the financial statements of the Company for the financial year ended 31st March 2018, as Annexure 1.

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, a declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2018 is also enclosed.

08-May-2018 06:52 PM

Sun Pharma Advanced - Submision Of PCS Certificate Under Regulation 40(9) Of SEBI (LODR) Regulation For The Half Year Ended 3

As per the requirements of Regulation 40(10) of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, please find herewith the Compliance Certificate dated 25th April 2018 issued by M/s. KJB & Co. LLP, Practicing Company Secretaries, for the half year ended 31st March 2018.

This is for your information and records.

26-Apr-2018 07:09 PM

Sun Pharma Advanced - Board Meeting-Outcome of Board Meeting

The Board of Directors of the Company at their meeting held from 04:45 pm to 06:45 pm today, inter alia, took on record and duly approved the Audited Financial Results for the quarter and year ended 31st March, 2018 which are enclosed along with the Auditors' Report on the financial statements of the Company for the financial year ended 31st March 2018, as Annexure 1.

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, a declaration by CFO confirming that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year ended 31st March 2018 is also enclosed.

08-May-2018 06:52 PM

Sun Pharma Advanced - Submision Of PCS Certificate Under Regulation 40(9) Of SEBI (LODR) Regulation For The Half Year Ended 3

As per the requirements of Regulation 40(10) of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, please find herewith the Compliance Certificate dated 25th April 2018 issued by M/s. KJB & Co. LLP, Practicing Company Secretaries, for the half year ended 31st March 2018.

This is for your information and records.

26-Apr-2018 07:09 PM

Sun Pharma Advanced - Board Meeting On 8Th May 2018 To Consider Annual Financial Results

Pursuant to regulation 29 (1) of the SEBI (Listing obligation & Disclosure Requirements) Regulation, 2015, we hereby inform you that a meeting of the Board of Directors of Sun Pharma Advanced Research Company Limited will be held on Tuesday, 8th May, 2018, inter alia, to consider and take on record, the audited financial results of the Company for the financial year ended 31st March 2018.

Further, kindly note that pursuant to the Company's Code of Internal Procedures and Code of Conduct for Prevention of Insider Trading, the trading window for trading by designated persons shall be closed from Thursday, 26th April 2018 to Thursday, 10th May, 2018 (both days inclusive) in view of the above.

24-Apr-2018 12:43 PM

Corporate Details

About Management

2007 - Sun Pharma Advanced Research Co.Ltd was formed in the year 2007, with separation of India's leading specialty pharma company, Sun Pharmaceutical Industries Ltd, and its active projects in drug discovery and innovation into a new company. The parent company, Sun Pharma Industries Ltd continues to invest independently in generic research. - Sun Pharma Advanced Research Company Ltd (SPARCL) had allotted 3,39,441 equity shares of Re 1 each to the bond-holders of Sun Pharma Industries Ltd (SPIL) on conversion of 5,500 foreign currency convertible bonds upon conversion. - Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 adopted and the Reports of Directors & Auditors thereon. - Mr. Dilip S Shanghvi and Mr. Sudhir V Valia, re appointed as the Directors of the Company. - According to the clause 10.2 of the scheme of arrangement of demerger, sanctioned by the High Court of Gujarat through its order dated March 01, 2007, issued on March 28, 2007 and as per supplementary Trust Deed dated may 18, 2007, the FCCB's holders of Sun Pharma Industries Ltd, are entitled for one equity share of Re 1 each of the company for every equity share of Rs.5 each of SPIL. 2011 - "Sun Pharma announces USFDA approval for DOCEFREZ (docetaxel) for Injection". 2012 -SPARC - Starhaler Device finalist at Medical Design Excellence Awards -Sun Pharma Advanced Research Company Ltd Issues Rights in the Ratio of 1:7 2013 -SPARC to provide update on NCE & NDDS programs 2014 -SPARC Announces India Approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN) 2017 - SPARC has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg.

Registered Office

17-B, Mahal Industrial Estate, Mahakali Caves Road, Andheri (East)

,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.